These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7144688)

  • 41. Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients.
    Miach PJ; Thomson W; Doyle AE; Louis WJ
    Med J Aust; 1976 Sep; 2(10):378-80. PubMed ID: 792640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicentre study comparing mazindol and placebo in obese patients.
    Walker BR; Ballard IM; Gold JA
    J Int Med Res; 1977; 5(2):85-90. PubMed ID: 326596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity.
    Enzi G; Baritussio A; Marchiori E; Crepaldi G
    J Int Med Res; 1976; 4(5):305-18. PubMed ID: 1028632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mazindol and growth hormone inhibition in Duchenne muscular dystrophy.
    Zatz M; Vainzof M; Rapaport D; da Rocha JM; Pavanello Rde C; Betti RT
    Am J Med Genet; 1987 Aug; 27(4):993-5. PubMed ID: 3321999
    [No Abstract]   [Full Text] [Related]  

  • 45. [Mazindol].
    Mori Y
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():683-6. PubMed ID: 21766681
    [No Abstract]   [Full Text] [Related]  

  • 46. [Activity-mobilizing lipids and blood lipids in patients treated with Mazindol].
    Hasik J; Gryczka AZ; Paluszak J; Tycowa M
    Pol Arch Med Wewn; 1978 Nov; 60(5):401-4. PubMed ID: 724542
    [No Abstract]   [Full Text] [Related]  

  • 47. The effect of an anorectic agent (Mazindol) on control of obese diabetics.
    Sanders M; Breidahl H
    Med J Aust; 1976 Oct; 2(15):576-7. PubMed ID: 994969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mazindol in the treatment of narcolepsy.
    Parkes JD; Schachter M
    Acta Neurol Scand; 1979 Oct; 60(4):250-4. PubMed ID: 525256
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Importance of mazindol in the treatment of narcolepsy.
    Vespignani H; Barroche G; Escaillas JP; Weber M
    Sleep; 1984; 7(3):274-5. PubMed ID: 6484432
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of cocaine abuse with mazindol.
    Berger P; Gawin F; Kosten TR
    Lancet; 1989 Feb; 1(8632):283. PubMed ID: 2563451
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.
    Coakley JH; Moorcraft J; Hipkin LJ; Smith CS; Griffiths RD; Edwards RH
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1551-7. PubMed ID: 3221222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mazindol in Duchenne muscular dystrophy.
    Coakley JH; Edwards RH; Moorcraft J; Hipkin LJ; Smith CS
    Lancet; 1988 Jan; 1(8578):184. PubMed ID: 2893022
    [No Abstract]   [Full Text] [Related]  

  • 53. Mazindol in the control of micturition.
    Woodhouse CR; Tiptaft RC
    Br J Urol; 1983 Dec; 55(6):636-8. PubMed ID: 6360295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mazindol for nocturnal enuresis.
    Tiptaft RC; Woodhouse CR; Badenoch DF
    Br J Urol; 1984 Dec; 56(6):641-3. PubMed ID: 6534482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mazindol in the treatment of Parkinson's disease.
    Delwaide PJ; Martinelli P; Schoenen J
    Arch Neurol; 1983 Dec; 40(13):788-90. PubMed ID: 6357158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Value of mazindol in Gélineau's disease. Apropos of 10 cases].
    Vespignani H; Weber M; Atlas P; Barroche G
    Rev Electroencephalogr Neurophysiol Clin; 1986 Oct; 16(3):317-22. PubMed ID: 3809694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of a growth hormone inhibitor on the course of Duchenne's myopathy].
    Serratrice G; Desnuelle C
    Presse Med; 1988 Nov; 17(41):2201. PubMed ID: 2974583
    [No Abstract]   [Full Text] [Related]  

  • 58. [Modification of serum lipid values and of the neurovegetative equilibrium in subjects under mazindol therapy].
    Zdichynec B; Rechmani BA
    Cesk Gastroenterol Vyz; 1979 Jan; 33(1):51-7. PubMed ID: 369713
    [No Abstract]   [Full Text] [Related]  

  • 59. The effects of calcium channel blocker benidipine and calmodulin antagonist W7 on GDP-binding capacity of brown adipose tissue in mice.
    Song YM; Lin PY; Chen MD
    Biol Trace Elem Res; 2009 Mar; 127(3):245-50. PubMed ID: 18953505
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Drug treatment of obesity].
    Meinders AE; Toornvliet AC; Pijl H
    Ned Tijdschr Geneeskd; 1996 Aug; 140(32):1632-4. PubMed ID: 8815403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.